RCS - Angle PLC - Parsortix system showcased at ACTC conference

AngleAnnouncement

29/09/2023 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230929:nRSc0592Oa&default-theme=true

RNS Number : 0592O  Angle PLC  29 September 2023

 For immediate release  29 September 2023

 

ANGLE plc ("the Company")

 

PARSORTIX SYSTEM SHOWCASED AT 'Advances in Circulating Tumor Cells' conference

 

Nine poster presentations utilising the Parsortix system in six cancer types
all received positive feedback

 

ANGLE plc (AIM:AGL OTCQX:ANPCY), a world-leading liquid biopsy company with
innovative circulating tumour cell (CTC) diagnostic solutions for use in
research, drug development and clinical oncology, is pleased to announce its
participation at the 6(th) Advances in Circulating Tumor Cells (ACTC)
conference held in Greece from 20-23 September 2023.

 

The conference brought together translational researchers and industry
participants to discuss the latest developments and clinical applications of
liquid biopsy and advances in precision oncology. This included the
presentation of nine posters showcasing the Parsortix(®) system in six cancer
types across eight independent study centres.

 

Conference highlights utilising the Parsortix system include:

 

·    A study by the Fondazione IRCCS Istituto Nazionale dei Tumori, Italy,
investigating the relevance of CTC biomarkers for monitoring treatment
response in Non-Small Cell Lung Cancer (NSCLC). The study in 60 patients,
found that CTC-based biomarkers were predictive of treatment resistance and
that PD-L1+ CTCs might be used to select patients for immunotherapy.

 

·    Three posters in lung, pancreatic and bone cancer respectively,
reporting on the potential clinical significance of mesenchymal CTCs which
would have been missed if traditional epithelial label-dependent CTC capture
methods had been utilised.

 

·    Two posters showcasing dual analysis of CTCs and ctDNA, highlighting
the growing interest in the addition of CTC analysis to ctDNA assays as a
means to provide information on gene expression (RNA) and proteins, with data
providing increasing evidence that RNA analysis can provide clinicians with
additional targeted treatment options.

 

 

ANGLE Chief Scientific Officer, Karen Miller, commented:

"We were pleased to see the Parsortix system being showcased at the ACTC
conference by translational researchers from seven European countries in
patients across a breadth of cancers including lung, breast, prostate,
pancreatic, thyroid and bone. ANGLE received extremely positive feedback on
the Parsortix system and, in particular, our plans for new assays to provide
content for the Parsortix system.  We look forward to expanding our
translational research use through our international distributors whilst
continuing to grow our biopharma services business."

 

 

 

For further information:

 

 ANGLE plc                               +44 (0) 1483 343434

 Andrew Newland, Chief Executive

 Ian Griffiths, Finance Director

 Berenberg (NOMAD and Joint Broker)      +44 (0) 20 3207 7800

 Toby Flaux, Ciaran Walsh, Milo Bonser

 Jefferies (Joint Broker)                +44 (0) 20 7029 8000

 Thomas Bective, Shaam Vora

 FTI Consulting

 Simon Conway, Ciara Martin              +44 (0) 203 727 1000

 Matthew Ventimiglia (US)                +1 (212) 850 5624

 

 

For Research Use Only. Not for use in diagnostic procedures.

 

For Frequently Used Terms, please see the Company's website on
https://angleplc.com/investor-relations/glossary/
(https://angleplc.com/investor-relations/glossary/)

 

 

Notes for editors

 

About ANGLE plc

 

ANGLE is a world-leading liquid biopsy company with innovative circulating
tumour cell (CTC) diagnostic solutions for use in research, drug development
and clinical oncology using a simple blood sample. ANGLE's FDA cleared and
patent protected circulating tumour cell (CTC) harvesting technology known as
the Parsortix(®) PC1 System enables complete downstream analysis of the
sample including whole cell imaging and proteomic analysis and full genomic
and transcriptomic molecular analysis.

 

ANGLE's commercial businesses are focusing on diagnostic products and clinical
services. Diagnostic products include the Parsortix(®) system and associated
consumables. The clinical services business is offered through ANGLE's
GCP-compliant laboratories in the UK and the United States.  Services include
custom made assay development and clinical trial testing for pharma.

 

Over 80 peer-reviewed publications have demonstrated the performance of the
Parsortix system. For more information, visit www.angleplc.com
(http://www.angleplc.com)

 

 

 

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAEVLFLXKLEBBZ